Everolimus in postmenopausal ER + Metastatic Breast Cancer patients

• Research type

  Research Study

• Full title

  An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive metastatic breast cancer.

• IRAS ID

  114217

• Contact name

  Mark Beresford

• Contact email

  mark.beresford@nhs.net

• Sponsor organisation

  Novartis Pharmaceuticals

• Eudract number

  2012-003065-17

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  13/SC/0136

• Date of REC Opinion

  16 May 2013

• REC opinion

  Further Information Favourable Opinion